secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269722
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Rani Therapeutics reports Q3 2025 results, announces $1.085B Chugai collaboration and $60.3M financing
--------------------------------------------------------------------------------

- Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.
- Closed $60.3M oversubscribed private placement led by Samsara BioCapital with participation from RA Capital, Anomaly, Special Situations Funds, and Invus.
- Appointed Abraham Bassan (Samsara BioCapital) and Vasudev Bailey, Ph.D. (Anomaly Ventures) to the Board of Directors.
- Cash runway expected into 2028; Phase 1 trial of oral obesity therapy RT-114 planned by end of 2025.
- Net loss for Q3 2025 was $7.9M, improved from $12.7M in prior year period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312525269722/0001193125-25-269722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312525269722/rani-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer